Azilect Articles

ANN meeting highlights: Novartis' Gilenya, Lundbeck's Azilect, Orion's ODM-101, Biotie's tozadenant

21 March 2013

Patient share of Teva/Lundbeck's Azilect for Parkinson's continues to grow

1 August 2012

Teva gets EU clearance for Cephalon acquisition; negative review on Azilect

14 October 2011

Teva 2nd-qtr 2011 US sales downturn compensated by strong European showing

27 July 2011

Variations in Parkinson's disease treatment among prescribers in France, Germany, Italy, Spain and the UK

2 December 2010

Watson in partnership with Moksha8 for Brazil and Mexico, inc $30M investment; files for generic Azilect

6 October 2010

Teva returns to profit, as 4th quarter 2009 sales leap 33%

16 February 2010

Lundbeck shares driven up by higher profit

15 May 2009

Teva's 1st-qtr profit more than triples

6 May 2009

Lundbeck's 2008 net profit drops 15%

16 March 2009

Azilect helps "double 2nd-line MAO-Bs in PD"

16 March 2009

Teva profit down 67% on Barr merger costs

23 February 2009

Lundbeck's 3rd-qtr 2008 net profit drops 11%

24 November 2008

PROUD trial due to show results in 2009

8 September 2008

Teva's Azilect meets all endpoints in ADAGIO trial

8 September 2008

Lundbeck profit down 52% on Flurizan failure

1 September 2008

Teva's 2nd-qtr 2008 profit up 5% to $539M

18 August 2008

Teva targets Japanese market, says CEO

4 August 2008

Teva says Azilect slows progression of PD

23 June 2008

Teva's 4th-qtr income climbs 24% US sales

18 February 2008

Lundbeck's 3rd-qtr net profit soars 67%

3 December 2007

Teva invests $1M in Israel's Cellcure Neurosci

10 September 2007

Lundbeck's 2nd-qtr 2007 revenue increases 19%

3 September 2007

Teva's 2nd-qtr 2007 net sales rise 10% to $2.39B

20 August 2007

H Lundbeck's profit drops 30% for 2006

26 March 2007

Teva's 4th-qtr profits up 42%, but EPS falls short

19 February 2007

Enrollment complete in landmark ADAGIO trial

8 January 2007

Strong data for Teva/Lundbeck's Azilect as adjunct

11 September 2006

H Lundbeck' 2nd-qtr profits fall 69%

28 August 2006

Teva's Azilect approved for early PD in Canada

28 August 2006

Japan stock market week to July 17, 2006

24 July 2006

Teva and Eisai halt US collaboration on rasagiline

17 July 2006

US FDA clears Teva's Azilect for early PD

29 May 2006

H Lundbeck's 2005 net profits down 6%

27 March 2006

First patients enrolled in Teva's ADAGIO study

19 December 2005

Patient enrollment starts in Teva's Azilect study

12 December 2005

Teva to continue talks with FDA on Agilect NDA

15 August 2005

Teva's 2nd-qtr lifted by non-US business

8 August 2005

Teva's Azilect: long-term benefits in PD

13 June 2005

Teva 1st-qtr net profit leaps 26%

16 May 2005

Encouraging data for Agilect

14 March 2005

Teva/Lundbeck's Azilect cleared for PD in EU

28 February 2005

PRESTO study shows Agilect improves motor function and Parkinson's symptoms

21 February 2005

Teva's 4th-qtr income soars 40%

21 February 2005

Teva's Azilect gets first approval in Israel

10 January 2005

Eisai 1st-half sales on target, rising 5.3%

15 November 2004

Positive data for Teva's Agilect

13 September 2004

FDA approvable letter for Teva's Agilect

12 July 2004

Early therapy with rasagiline beneficial

3 May 2004

Rasagiline reduces "off" time in PD

27 October 2003

Teva's rasagiline filed in EU as PD therapy

20 October 2003

Tokyo pharma stocks - week to Sept 15

22 September 2003

Teva seeks US approval of rasagiline for PD

15 September 2003

Tokyo pharma stocks - week to June 2

9 June 2003

Stock Commentary - Tokyo

9 June 2003

Teva and Eisai link up on CNS drug rasagiline

19 May 2003

Teva and Lundbeck set to file rasagiline for Parkinson's disease in second half

31 March 2003

Teva's rasagiline promising in early Parkinson's?

20 January 2003

Lundbeck profits soar 54% in 2000 as citalopram sales boom

7 March 2001

Teva sales for full-year 2000 reach $1.75 billion as Copaxone forges ahead

16 February 2001

Huge earnings rise at Denmark's Lundbeck

16 August 2000

Teva progresses in CNS and autoimmune drugs

31 July 2000

Teva and Lundbeck boosted on PD drug

12 April 2000

Lundbeck and Teva hook up in CNS

25 November 1999

First Approval Of Teva's MS Drug Copaxone

25 November 1996

Teva profit falls 57% on acquisition charges